Get Live Data
Less Ads, More Data, More Tools Register for FREE
REMOVE ADS
REMOVE ADS

Latest Share Chat

  2. Share Prices
  3. Astrazeneca Share Price
  4. Astrazeneca Share Regulatory News
  5. Director Declaration

Pin to quick picksAstrazeneca Regulatory News (AZN)

Astrazeneca Information

Share Price Information for Astrazeneca (AZN)

Share Price is delayed by 15 minutes
Get Live Data
13,858.00    304.00 (2.24%)
Bid:
13,842.00
Ask:
13,846.00
Spread: 4.00 (0.029%)
Market Cap: £214.92b
AZN Live PriceLast checked at - London Stock Exchange

Intraday Astrazeneca Share Chart

Director Declaration

28 Oct 2025 07:05

RNS Number : 9938E
AstraZeneca PLC
28 October 2025
 

 

 

28 October 2025

 

Director Declaration

 

AstraZeneca PLC (the Company) today announced that Euan Ashley, Non-Executive Director of the Company, has been appointed a director of DexCom, Inc. with effect from 24 October 2025.

 

This announcement is made pursuant to Listing Rule 6.4.9 (2).

 

 

AstraZeneca AstraZeneca (LSE/STO/Nasdaq: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development, and commercialisation of prescription medicines in Oncology, Rare Diseases, and BioPharmaceuticals, including Cardiovascular, Renal & Metabolism, and Respiratory & Immunology. Based in Cambridge, UK, AstraZeneca's innovative medicines are sold in more than 125 countries and used by millions of patients worldwide. Please visit astrazeneca.com and follow the Company on Social Media @AstraZeneca.

 

Contacts For details on how to contact the Investor Relations Team, please click here. For Media contacts, click here.

 

 

Matthew BowdenCompany Secretary

AstraZeneca PLC

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
RDNQDLFLEBLZFBZ
12345678910
Date   Source Headline
1st Jun 20263:05 pmRNSAdmission of Further Securities to Trading
1st Jun 20263:00 pmRNSTotal Voting Rights
29th May 20267:00 amRNSImfinzi approved in US for early bladder cancer
27th May 20267:00 amRNSUS FDA decision date on camizestrant extended
26th May 20267:00 amRNSEnhertu recommended in EU for HER2+ solid tumours
26th May 20267:00 amRNSCamizestrant recommended for breast cancer in EU
26th May 20267:00 amRNSDatroway approved in US for 1L triple-negative BC
18th May 20263:00 pmRNSDirector/PDMR Shareholding
18th May 20267:05 amRNSEnhertu approved in two HER2+ early BC settings
18th May 20267:00 amRNSBaxfendy approved in the US for hypertension
14th May 20267:00 amRNSImfinzi + EV improves EFS & OS in bladder cancer
1st May 20263:00 pmRNSTotal Voting Rights and Admission of Shares
1st May 20267:05 amRNSFDA ODAC vote on camizestrant in breast cancer
1st May 20267:00 amRNSFDA ODAC recommends Truqap in prostate cancer
29th Apr 20267:00 amRNS1st Quarter Results
28th Apr 20267:00 amRNSBreztri approved in the US for asthma
27th Apr 20267:00 amRNSSaphnelo self-administration approved in the US
23rd Apr 20267:00 amRNSDirectorate change
21st Apr 20267:00 amRNSI CAN PhIII interim analysis met primary endpoint
20th Apr 20267:00 amRNSThird tozorakimab positive Phase III in COPD
9th Apr 20265:15 pmRNSResult of AGM
2nd Apr 20267:00 amRNSImfinzi+Imjudo improves PFS in early liver cancer
1st Apr 20263:00 pmRNSTotal Voting Rights and Admission of Shares
31st Mar 20267:00 amRNSEfzimfotase alfa Ph3 program show positive results
27th Mar 20267:00 amRNSTozorakimab met OBERON/TITANIA primary endpoints
20th Mar 202611:00 amRNSNotification of Admission of Shares
16th Mar 20267:00 amRNSImfinzi approved in EU for early gastric cancer
16th Mar 20267:00 amRNSImfinzi approved in EU for early gastric cancer
10th Mar 202611:00 amRNSNotice of AGM
10th Mar 202611:00 amRNSNotice of AGM
6th Mar 202611:10 amRNSDirector/PDMR Shareholding
6th Mar 202611:05 amRNSDirector/PDMR Shareholding
6th Mar 202611:00 amRNSDirector/PDMR Shareholding
2nd Mar 20263:00 pmRNSTotal Voting Rights
26th Feb 20267:00 amRNSAstraZeneca prices a $2bn bond offering
25th Feb 20267:00 amRNSFiling of Form 20-F with SEC
24th Feb 202611:00 amRNSAnnual Financial Report
24th Feb 20267:00 amRNSDirectorate change
20th Feb 20267:00 amRNSFixed-duration Calquence combo approved in US
10th Feb 20267:00 amRNSFinal Results
3rd Feb 20267:00 amRNSUpdate on Saphnelo subcutaneous administration
2nd Feb 20263:00 pmRNSTotal Voting Rights
2nd Feb 20267:05 amRNSImfinzi recommended in EU for early gastric cancer
2nd Feb 20267:00 amRNSAstraZeneca begins trading on NYSE
30th Jan 20267:00 amRNSAstraZeneca agrees obesity and T2D deal with CSPC
29th Jan 20269:51 amRNSAstraZeneca invests $15bn in China through 2030
20th Jan 20267:00 amRNSAstraZeneca to complete direct listing on NYSE
8th Jan 20267:00 amRNSAZN new Head of Investor Relations Joris Silon
2nd Jan 20263:00 pmRNSTotal Voting Rights
22nd Dec 202511:00 amRNSDirector/PDMR Shareholding
12345678910

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Recently viewed
HHI
Henderson High Income Trust
LSE
0.00%
TGGD
Jh Gcc Gd
LSE
-0.53%
TTE
Totalenergies
LSE
2.70%
BEMO
Barings Emerg.
LSE
1.27%
COR
Corpus Resources PLC
LSE
0.00%
Trending
ITM
Itm Power
LSE
-10.85%
GST
GSTechnologies
LSE
8.11%
PPP
Pennpetro Energy
LSE
0.00%
EZJ
easyJet
LSE
0.34%
NANO
Nanoco
LSE
-10.69%